Yes / The HOX and PBX gene families encode transcription factors that have key roles
in establishing the identity of cells and tissues in early development. Over the last 20
years it has become apparent that they are also dysregulated in a wide range of solid
and haematological malignancies and have a predominantly pro-oncogenic function.
A key mode of transcriptional regulation by HOX and PBX proteins is through their
interaction as a heterodimer or larger complex that enhances their binding affinity and
specificity for DNA, and there is growing evidence that this interaction is a potential
therapeutic target in malignancies that include prostate, breast, renal, ovarian
and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review
summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic
potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its
application in precision medicine.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/11620 |
| Date | 07 March 2017 |
| Creators | Morgan, Richard, El-Tanani, Mohamed, Hunter, K.D., Harrington, K.J., Pandha, H.S. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Published version |
| Rights | © 2017 Morgan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
Page generated in 0.0019 seconds